1. Home
  2. ARTL vs LIPO Comparison

ARTL vs LIPO Comparison

Compare ARTL & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • LIPO
  • Stock Information
  • Founded
  • ARTL 2011
  • LIPO 2005
  • Country
  • ARTL United States
  • LIPO United States
  • Employees
  • ARTL N/A
  • LIPO N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • LIPO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • LIPO Health Care
  • Exchange
  • ARTL Nasdaq
  • LIPO Nasdaq
  • Market Cap
  • ARTL 3.6M
  • LIPO 3.1M
  • IPO Year
  • ARTL N/A
  • LIPO 2022
  • Fundamental
  • Price
  • ARTL $0.95
  • LIPO $2.59
  • Analyst Decision
  • ARTL Strong Buy
  • LIPO Strong Buy
  • Analyst Count
  • ARTL 2
  • LIPO 1
  • Target Price
  • ARTL $5.50
  • LIPO $16.00
  • AVG Volume (30 Days)
  • ARTL 15.8K
  • LIPO 46.4K
  • Earning Date
  • ARTL 03-03-2025
  • LIPO 05-08-2025
  • Dividend Yield
  • ARTL N/A
  • LIPO N/A
  • EPS Growth
  • ARTL N/A
  • LIPO N/A
  • EPS
  • ARTL N/A
  • LIPO N/A
  • Revenue
  • ARTL N/A
  • LIPO $536,357.00
  • Revenue This Year
  • ARTL N/A
  • LIPO N/A
  • Revenue Next Year
  • ARTL N/A
  • LIPO N/A
  • P/E Ratio
  • ARTL N/A
  • LIPO N/A
  • Revenue Growth
  • ARTL N/A
  • LIPO 0.78
  • 52 Week Low
  • ARTL $0.91
  • LIPO $2.02
  • 52 Week High
  • ARTL $1.60
  • LIPO $12.00
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 39.95
  • LIPO 48.74
  • Support Level
  • ARTL $0.95
  • LIPO $2.16
  • Resistance Level
  • ARTL $1.04
  • LIPO $2.74
  • Average True Range (ATR)
  • ARTL 0.03
  • LIPO 0.19
  • MACD
  • ARTL 0.01
  • LIPO 0.06
  • Stochastic Oscillator
  • ARTL 36.51
  • LIPO 78.87

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

About LIPO Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Share on Social Networks: